Evidence map›Paper›PMID 23052553›Full record

ArticleZeitschrift fur Rheumatologie2012

[Is treat to target compatible with health insurance and health insurance funds?].

J Wendler, E Edelmann

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

J WendlerRheumatologische Schwerpunktpraxis Erlangen, Möhrendorfer Str. 1c, 91056, Erlangen, Deutschland. joerg.wendler-erlangen@t-online.de
E Edelmann
Praxis für Humangenetik · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Can treat to target (T2T) evidence-based recommendations of the T2T initiative in routine outpatient care be implemented in Germany? Regional selective agreements were made with individual health insurance companies, which included among others structured assessment, target-oriented basic therapy and tight control. A federal universal implementation seems, however, to be distant. A substantial deficit is the poor availibility of rheumatological care. In the currently implemented routine care by health insurance institutions a realization of the T2T recommendations is not only impossible but even impeded. Selective agreements and outpatient specialist treatment of the new treatment structure act make allowances for rheumatological treatment but only the practical implementation will reveal the true possibilities. The current situation needs a national action plan for rheumatological care by which the content of T2T can be implemented.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidGermanyHealth Care CostsHumansInsurance, Health, ReimbursementNational Health ProgramsAntirheumatic Agents

Identifiers

PMID23052553
OpenAlexW187757929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.